<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03387111</url>
  </required_header>
  <id_info>
    <org_study_id>QUILT-3.090</org_study_id>
    <nct_id>NCT03387111</nct_id>
  </id_info>
  <brief_title>QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Subjects With SCC Who Have Progressed</brief_title>
  <official_title>QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Molecularly Informed Integrated Immunotherapy Combining (haNK) Cell Therapy With Adenoviral and Yeast-based Vaccines to Induce T-cell Responses in Subjects With SCC Who Have Progressed on or After Platinum-based Chemotherapy and Anti-programmed Cell Death Protein 1 (PD-1)/Programmed Death-ligand 1 (PD-L1) Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ImmunityBio, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ImmunityBio, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 1b/2 study to evaluate the safety and efficacy of metronomic combination&#xD;
      therapy in subjects with SCC who have progressed on or after previous platinum-based&#xD;
      chemotherapy and anti-PD-1/PD-L1 therapy. Phase 2 will be based on Simon's two-stage optimal&#xD;
      design.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Treatment will be administered in 2 phases, an induction and a maintenance phase, as&#xD;
      described below. Subjects will continue induction treatment for up to 1 year. Treatment in&#xD;
      the study will be discontinued if the subject experiences progressive disease (PD) or&#xD;
      unacceptable toxicity (not corrected with dose reduction), withdraws consent, or if the&#xD;
      Investigator feels it is no longer in the subject's best interest to continue treatment.&#xD;
      Those who have a complete response (CR) in the induction phase will enter the maintenance&#xD;
      phase of the study. Subjects who experience ongoing stable disease (SD) or an ongoing partial&#xD;
      response (PR) at 1 year may enter the maintenance phase at the Investigator's and Sponsor's&#xD;
      discretion. Subjects may remain in the maintenance phase of the study for up to 1 year. The&#xD;
      duration of the maintenance phase can exceed 1 year if the subject continues to benefit, per&#xD;
      the Investigator's and Sponsor's discretion. Treatment will continue in the maintenance phase&#xD;
      until the subject experiences PD or unacceptable toxicity (not corrected with dose&#xD;
      reduction), withdraws consent, or if the Investigator feels it is no longer in the subject's&#xD;
      best interest to continue treatment. The time on study treatment, including both the&#xD;
      induction and maintenance phases, is up to 2 years. The duration of the study may exceed 2&#xD;
      years if the subject remains in the maintenance phase for more than 1 year, as described&#xD;
      above.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 13, 2018</start_date>
  <completion_date type="Anticipated">April 2021</completion_date>
  <primary_completion_date type="Anticipated">January 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of treatment-emergent Adverse Events (AEs) and Serious Adverse Events (SAEs), graded using the NCI CTCAE Version 4.03.</measure>
    <time_frame>8 weeks</time_frame>
    <description>Phase 1b primary endpoint</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective response rate by RECIST</measure>
    <time_frame>1 year</time_frame>
    <description>Phase 2 primary endpoint</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate by RECIST</measure>
    <time_frame>8 weeks</time_frame>
    <description>Phase 1b secondary endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate by irRC</measure>
    <time_frame>8 weeks</time_frame>
    <description>Phase 1b secondary endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival by RECIST during Phase 1b</measure>
    <time_frame>8 weeks</time_frame>
    <description>Phase 1b secondary endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival by irRC during Phase 1b</measure>
    <time_frame>8 weeks</time_frame>
    <description>Phase 1b secondary endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>8 weeks</time_frame>
    <description>Phase 1b secondary endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response by RECIST and irRC</measure>
    <time_frame>1 year</time_frame>
    <description>Phase 1b secondary endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (confirmed complete response, partial response, or stable disease lasting for at least 2 months) by RECIST and irRC.</measure>
    <time_frame>1 year</time_frame>
    <description>Phase 1b secondary endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient-reported outcomes of pancreatic cancer symptoms</measure>
    <time_frame>8 weeks</time_frame>
    <description>Phase 1b secondary endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate by irRC</measure>
    <time_frame>1 year</time_frame>
    <description>Phase 2 secondary endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival by RECIST during Phase 2</measure>
    <time_frame>1 year</time_frame>
    <description>Phase 2 secondary endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival by irRC during Phase 2</measure>
    <time_frame>1 year</time_frame>
    <description>Phase 2 secondary endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>1 year</time_frame>
    <description>Phase 2 secondary endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response by RECIST and irRC</measure>
    <time_frame>1 year</time_frame>
    <description>Phase 2 secondary endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (confirmed complete response, partial response, or stable disease lasting for at least 2 months) by RECIST and irRC.</measure>
    <time_frame>1 year</time_frame>
    <description>Phase 2 secondary endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient-reported outcomes of pancreatic cancer symptoms</measure>
    <time_frame>1 year</time_frame>
    <description>Phase 2 secondary endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment-emergent Adverse Events (AEs) and Serious Adverse Events (SAEs), graded using the NCI CTCAE Version 4.03.</measure>
    <time_frame>1 year</time_frame>
    <description>Phase 2 secondary endpoint</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">65</enrollment>
  <condition>Squamous Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>NANT Squamous Cell Carcinoma (SCC) Vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combination of agents will be administered in this study: Aldoxorubicin HCl, ETBX-011, ETBX-021, ETBX-051, ETBX-061, GI-4000, GI-6207, GI-6301, haNK, N-803, avelumab, bevacizumab, capecitabine, cetuximab, cisplatin, cyclophosphamide, fluorouracil, leucovorin, nab-paclitaxel, necitumumab, SBRT.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aldoxorubicin HCl</intervention_name>
    <description>Aldoxorubicin hydrochloride</description>
    <arm_group_label>NANT Squamous Cell Carcinoma (SCC) Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ETBX-011</intervention_name>
    <description>Ad5 [E1-, E2b-]-CEA</description>
    <arm_group_label>NANT Squamous Cell Carcinoma (SCC) Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ETBX-021</intervention_name>
    <description>Ad5 [E1-, E2b-]-HER2</description>
    <arm_group_label>NANT Squamous Cell Carcinoma (SCC) Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ETBX-051</intervention_name>
    <description>Ad5 [E1-, E2b-]-Brachyury vaccine</description>
    <arm_group_label>NANT Squamous Cell Carcinoma (SCC) Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ETBX-061</intervention_name>
    <description>Ad5 [E1-, E2b-]-MUC1</description>
    <arm_group_label>NANT Squamous Cell Carcinoma (SCC) Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GI-4000</intervention_name>
    <description>Vaccine derived from recombinant Saccharomyces cerevisiae yeast expressing mutant Ras proteins</description>
    <arm_group_label>NANT Squamous Cell Carcinoma (SCC) Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GI-6207</intervention_name>
    <description>Vaccine derived from recombinant Saccharomyces cerevisiae yeast expressing mutant CEA proteins</description>
    <arm_group_label>NANT Squamous Cell Carcinoma (SCC) Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GI-6301</intervention_name>
    <description>Vaccine derived from recombinant Saccharomyces cerevisiae yeast expressing mutant Brachyury yeast proteins</description>
    <arm_group_label>NANT Squamous Cell Carcinoma (SCC) Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>haNK for infusion</intervention_name>
    <description>NK-92 [CD16.158V, ER IL-2]</description>
    <arm_group_label>NANT Squamous Cell Carcinoma (SCC) Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Avelumab</intervention_name>
    <description>Recombinant human anti-PD-L1 IgG1 monoclonal antibody</description>
    <arm_group_label>NANT Squamous Cell Carcinoma (SCC) Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bevacizumab</intervention_name>
    <description>Recombinant human anti-VEGF IgG1 monoclonal</description>
    <arm_group_label>NANT Squamous Cell Carcinoma (SCC) Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>5'-deoxy-5-fluoro-N-[(pentyloxy) carbonyl]-cytidine</description>
    <arm_group_label>NANT Squamous Cell Carcinoma (SCC) Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetuximab</intervention_name>
    <description>Cetuximab is an epidermal growth factor receptor (EGFR) antagonist.</description>
    <arm_group_label>NANT Squamous Cell Carcinoma (SCC) Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>cis-diamminedichloroplatinum(II)</description>
    <arm_group_label>NANT Squamous Cell Carcinoma (SCC) Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>2-[bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate</description>
    <arm_group_label>NANT Squamous Cell Carcinoma (SCC) Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluorouracil</intervention_name>
    <description>5-fluoro-2,4 (1H,3H)-pyrimidinedione</description>
    <arm_group_label>NANT Squamous Cell Carcinoma (SCC) Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leucovorin</intervention_name>
    <description>L-Glutamic acid, N-[4-[[(2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl]amino]benzoyl]-, calcium salt</description>
    <arm_group_label>NANT Squamous Cell Carcinoma (SCC) Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nab-Paclitaxel</intervention_name>
    <description>Benzenepropanoic acid, β-(benzoylamino)-α-hydroxy-(2aR, 4S, 4aS, 6R, 9S, 11S, 12S, 12aR, 12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a, 3, 4, 4a, 5, 6, 9, 10, 11, 12, 12a, 12b-dodecahydro-4,11-dihydroxy-4a, 8, 13, 13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-y1ester,(αR,βS)-(9CI) bound to albumin</description>
    <arm_group_label>NANT Squamous Cell Carcinoma (SCC) Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Necitumumab</intervention_name>
    <description>Necitumumab is a recombinant human lgG1 monoclonal antibody.</description>
    <arm_group_label>NANT Squamous Cell Carcinoma (SCC) Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>SBRT</intervention_name>
    <description>Stereotactic Body Radiation Therapy</description>
    <arm_group_label>NANT Squamous Cell Carcinoma (SCC) Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>N-803</intervention_name>
    <description>Recombinant human superagonist interleukin-15 (IL-15) complex [also known as IL-15N72D:IL-15RuSu/IgGI Fe complex1)</description>
    <arm_group_label>NANT Squamous Cell Carcinoma (SCC) Vaccine</arm_group_label>
    <other_name>Formerly known as ALT-803</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥ 18 years.&#xD;
&#xD;
          2. Able to understand and provide a signed informed consent that fulfills the relevant&#xD;
             IRB or Independent Ethics Committee (IEC) guidelines.&#xD;
&#xD;
          3. Histologically-confirmed HNSCC or squamous NSCLC with progression on or after&#xD;
             platinum-based chemotherapy and anti-PD-1/PD-L1 therapy.&#xD;
&#xD;
          4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.&#xD;
&#xD;
          5. Have at least 1 measurable lesion of ≥ 1.0 cm.&#xD;
&#xD;
          6. Must have a recent formalin-fixed, paraffin-embedded (FFPE) tumor biopsy specimen&#xD;
             following the conclusion of the most recent anticancer treatment. If an historic&#xD;
             specimen is not available, the subject must be willing to undergo a biopsy during the&#xD;
             screening period, if considered safe by the Investigator. If safety concerns preclude&#xD;
             collection of a biopsy during the screening period, a tumor biopsy specimen collected&#xD;
             prior to the conclusion of the most recent anticancer treatment may be used.&#xD;
&#xD;
          7. Must be willing to provide blood samples prior to the start of treatment on this&#xD;
             study.&#xD;
&#xD;
          8. Must be willing to provide a tumor biopsy specimen 8 weeks after the start of&#xD;
             treatment, if considered safe by the Investigator.&#xD;
&#xD;
          9. Ability to attend required study visits and return for adequate follow-up, as required&#xD;
             by this protocol.&#xD;
&#xD;
         10. Agreement to practice effective contraception for female subjects of child-bearing&#xD;
             potential and non-sterile males. Female subjects of child-bearing potential must agree&#xD;
             to use effective contraception for up to 1 year after completion of therapy, and&#xD;
             non-sterile male subjects must agree to use a condom for up to 4 months after&#xD;
             treatment. Effective contraception includes surgical sterilization (eg, vasectomy,&#xD;
             tubal ligation), two forms of barrier methods (eg, condom, diaphragm) used with&#xD;
             spermicide, intrauterine devices (IUDs), and abstinence.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Serious uncontrolled concomitant disease that would contraindicate the use of the&#xD;
             investigational drug used in this study or that would put the subject at high risk for&#xD;
             treatment-related complications.&#xD;
&#xD;
          2. Systemic autoimmune disease (eg, lupus erythematosus, rheumatoid arthritis, Addison's&#xD;
             disease, or autoimmune disease associated with lymphoma).&#xD;
&#xD;
          3. History of organ transplant requiring immunosuppression.&#xD;
&#xD;
          4. History of or active inflammatory bowel disease (eg, Crohn's disease, ulcerative&#xD;
             colitis).&#xD;
&#xD;
          5. Inadequate organ function, evidenced by the following laboratory results:&#xD;
&#xD;
               1. Absolute neutrophil count &lt; 1,000 cells//mm^3.&#xD;
&#xD;
               2. Uncorrectable grade 3 anemia (hemoglobin &lt; 8 g/dL).&#xD;
&#xD;
               3. Platelet count &lt; 75,000 cells/mm^3.&#xD;
&#xD;
               4. Total bilirubin greater than the upper limit of normal (ULN; unless the subject&#xD;
                  has documented Gilbert's syndrome).&#xD;
&#xD;
               5. Aspartate aminotransferase (AST [SGOT]) or alanine aminotransferase (ALT [SGPT])&#xD;
                  &gt; 2.5 × ULN (&gt; 5 × ULN in subjects with liver metastases).&#xD;
&#xD;
               6. Alkaline phosphatase levels &gt; 2.5 × ULN (&gt; 5 × ULN in subjects with liver&#xD;
                  metastases, or &gt;10 × ULN in subjects with bone metastases).&#xD;
&#xD;
               7. Serum creatinine &gt; 2.0 mg/dL or 177 μmol/L.&#xD;
&#xD;
               8. Serum anion gap &gt; 16 mEq/L or arterial blood with pH &lt; 7.3.&#xD;
&#xD;
          6. Uncontrolled hypertension (systolic &gt; 160 mm Hg and/or diastolic &gt; 110 mm Hg) or&#xD;
             clinically significant (ie, active) cardiovascular disease, cerebrovascular&#xD;
             accident/stroke, or myocardial infarction within 6 months prior to first study&#xD;
             medication; unstable angina; congestive heart failure of New York Heart Association&#xD;
             grade 2 or higher; or serious cardiac arrhythmia requiring medication. Subjects with&#xD;
             uncontrolled hypertension should be medically managed on a stable regimen to control&#xD;
             hypertension prior to study entry.&#xD;
&#xD;
          7. Serious myocardial dysfunction defined by ECHO as absolute left ventricular ejection&#xD;
             fraction (LVEF) 10% below the institution's lower limit of predicted normal.&#xD;
&#xD;
          8. Dyspnea at rest due to complications of advanced malignancy or other disease requiring&#xD;
             continuous oxygen therapy.&#xD;
&#xD;
          9. Positive results of screening test for human immunodeficiency virus (HIV).&#xD;
&#xD;
         10. Current chronic daily treatment (continuous for &gt; 3 months) with systemic&#xD;
             corticosteroids (dose equivalent to or greater than 10 mg/day methylprednisolone),&#xD;
             excluding inhaled steroids. Short-term steroid use to prevent IV contrast allergic&#xD;
             reaction or anaphylaxis in subjects who have known contrast allergies is allowed.&#xD;
&#xD;
         11. Known hypersensitivity to any component of the study medication(s).&#xD;
&#xD;
         12. Subjects taking any medication(s) (herbal or prescribed) known to have an adverse drug&#xD;
             reaction with any of the study medications.&#xD;
&#xD;
         13. Concurrent or prior use of a strong cytochrome P450 (CYP)3A4 inhibitor (including&#xD;
             ketoconazole, itraconazole, posaconazole, clarithromycin, indinavir, nefazodone,&#xD;
             nelfinavir, ritonavir, saquinavir, telithromycin, voriconazole, and grapefruit&#xD;
             products) or strong CYP3A4 inducers (including phenytoin, carbamazepine, rifampin,&#xD;
             rifabutin, rifapentin, phenobarbital, and St John's Wort) within 14 days before study&#xD;
             day 1.&#xD;
&#xD;
         14. Concurrent or prior use of a strong CYP2C8 inhibitor (gemfibrozil) or moderate CYP2C8&#xD;
             inducer (rifampin) within 14 days before study day 1.&#xD;
&#xD;
         15. Participation in an investigational drug study or history of receiving any&#xD;
             investigational treatment within 30 days prior to screening for this study, except for&#xD;
             testosterone-lowering therapy in men with prostate cancer.&#xD;
&#xD;
         16. Assessed by the Investigator to be unable or unwilling to comply with the requirements&#xD;
             of the protocol.&#xD;
&#xD;
         17. Concurrent participation in any interventional clinical trial.&#xD;
&#xD;
         18. Pregnant and nursing women.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Chan Soon-Shiong Institute for Medicine</name>
      <address>
        <city>El Segundo</city>
        <state>California</state>
        <zip>90245</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>December 21, 2017</study_first_submitted>
  <study_first_submitted_qc>December 28, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 29, 2017</study_first_posted>
  <last_update_submitted>August 10, 2020</last_update_submitted>
  <last_update_submitted_qc>August 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
    <mesh_term>Avelumab</mesh_term>
    <mesh_term>Necitumumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

